(MENAFN- GlobeNewsWire - Nasdaq) The hyperlipidemia drugs market is growing due to rising cardiovascular disease prevalence, increasing cholesterol management awareness, and aging populations. Opportunities lie in personalized and combination therapies, digital health integration, non-statin alternatives, and expanding markets in Asia-Pacific.Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Hyperlipidemia Drugs Market Report 2025" has been added to ResearchAndMarkets's offering.
The "Hyperlipidemia Drugs Global Market Report 2025" offers indispensable insights for strategists, marketers, and senior management to evaluate the hyperlipidemia drugs market, witnessing robust growth. This report highlights the emerging trends set to shape the market for the coming decade and beyond, aiding in strategic decision-making and market positioning.
![]()
The hyperlipidemia drugs market has experienced robust growth and is projected to expand from $23.36 billion in 2024 to $24.74 billion in 2025, with a CAGR of 5.9%. This expansion is driven by the increasing prevalence of cardiovascular conditions, increased awareness of cholesterol management, a higher incidence of obesity and diabetes, and a growing geriatric demographic embracing sedentary lifestyles.
Looking ahead, the market is anticipated to grow to $30.68 billion by 2029, registering a CAGR of 5.5%. Contributing factors include the rising demand for personalized medicine and targeted therapies, the adoption of combination therapies, and advancements in digital health and telemedicine. The development of non-statin alternatives, biosimilar advancements, and gene-editing innovations are notable trends expected during the forecast period.
The incidence of cardiovascular diseases, such as coronary heart disease and hypertension, is significantly influencing market growth. Poor dietary habits are a leading cause of these conditions, prompting an increased reliance on hyperlipidemia drugs for cholesterol management and patient outcome improvement. For instance, cardiovascular disease-related deaths in the U.S. increased by 4% in 2022, underscoring the urgent need for effective treatments.
Pharmaceutical innovators are developing combination therapies to enhance treatment efficiency and adherence. Notably, Daewoong Bio Inc. introduced CRA-TG Soft Capsule -a hybrid of rosuvastatin and omega-3 fatty acids- optimizing lipid management through a patented multi-layer capsule technology. Further consolidation in the industry is evident as Eli Lilly and Company acquired Verve Therapeutics Inc., aiming to develop gene-editing therapies targeting hyperlipidemia's genetic causes. This strategic move reflects a shift towards long-term solutions in cardiovascular treatment.
Leading market players include Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and others. In 2024, North America led market share, while Asia-Pacific is slated for rapid growth during the forecast period. Influencing factors include trade relations and tariffs, which have introduced challenges in sourcing APIs and essential materials. In response, companies are exploring production shifts and seeking trade exemptions to mitigate supply chain disruptions.
The hyperlipidemia drugs market encompasses various drug classes, such as statins and PCSK9 inhibitors, serving diverse end users via multiple distribution channels. The market's value reflects direct sales within specified regions, accounting for the economic activities associated with hyperlipidemia treatment products globally.
This detailed market research report offers a comprehensive insight into the hyperlipidemia drugs industry, tracking sales of niacin, omega-3 fatty acids, and other lipid management products. With updated analyses and recommendations, the report equips stakeholders with strategies to navigate this rapidly evolving industry landscape.
Reasons to Purchase:
Attain a comprehensive global view of the market across 15 geographies. Evaluate the influence of significant macro factors, including geopolitical tensions, trade policies, supply chain adjustments post-pandemic, inflation rate impacts, and regulatory changes. Develop regional and country-specific strategies based on local data analysis. Identify promising growth segments for investment. Excel over the competition using reliable forecast data, drivers, and trends shaping the market. Understand customer dynamics with up-to-date market share insights. Benchmark performance against competitors for strategic advantage. Enhance presentations with robust, high-quality data and analysis backed by an Excel dashboard for easy extraction.
Scope:
By Drug Class: Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, PCSK9 Inhibitors, Combination, Miscellaneous By Route of Administration: Oral, Parenteral, Others By Distribution Channel: Hospital, Online, Retail Pharmacies By End User: Hospitals, Clinics, Others
Subsegments:
By Statins: Atorvastatin, Rosuvastatin, Simvastatin, and more. By Bile Acid Sequestrants: Cholestyramine, Colesevelam, Colestipol By Cholesterol Absorption Inhibitors: Ezetimibe, Combinations By Fibric Acid Derivatives: Fenofibrate, Gemfibrozil, and others.
Key Companies Mentioned:
Pfizer Inc Merck & Co. Inc AbbVie Inc Sanofi S.A.
Key Attributes:
CONTACT:
CONTACT:
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment